MARKET

RAPP

RAPP

Rapport Therapeutics Inc
NASDAQ
14.60
-0.78
-5.07%
After Hours: 14.60 0 0.00% 16:04 07/11 EDT
OPEN
15.29
PREV CLOSE
15.38
HIGH
15.70
LOW
14.17
VOLUME
142.76K
TURNOVER
--
52 WEEK HIGH
29.74
52 WEEK LOW
6.43
MARKET CAP
532.86M
P/E (TTM)
-6.4924
1D
5D
1M
3M
1Y
5Y
1D
Rapport Therapeutics, Inc. (RAPP) Receives a Buy from Citizens JMP
TipRanks · 2d ago
Rapport Therapeutics Price Target Maintained With a $28.00/Share by JMP Securities
Dow Jones · 4d ago
JMP Securities Reiterates Market Outperform on Rapport Therapeutics, Maintains $28 Price Target
Benzinga · 4d ago
Citizens JMP pharmaceuticals analysts hold analyst/industry conference call
TipRanks · 4d ago
Weekly Report: what happened at RAPP last week (0630-0704)?
Weekly Report · 5d ago
Rapport Therapeutics files to sell 470,589 shares of common stock for holders
TipRanks · 07/01 11:00
RAPPORT THERAPEUTICS FILES PROSPECTUS RELATES TO PROPOSED RESALE FROM TIME TO TIME BY SELLING STOCKHOLDER OF UP TO 470,589 SHARES
Reuters · 07/01 10:57
Rapport Therapeutics files $400M mixed securities shelf
TipRanks · 07/01 10:55
More
About RAPP
Rapport Therapeutics, Inc. is a clinical-stage biotechnology company engaged in discovering and developing small-molecule precision medicines for patients with neurological or psychiatric disorders. It has made discoveries related to the function of receptor-associated proteins (RAPs) in the brain. Its RAP technology platform enables a differentiated approach to generate precision small molecule product candidates with the potential to overcome many limitations of conventional neurology drug discovery. Its precision neuroscience pipeline includes its lead investigational drug, RAP-219, designed to achieve neuroanatomical specificity through its selective targeting of a RAP expressed in only discrete regions of the brain. It is pursuing RAP-219 as a treatment for refractory focal epilepsy, bipolar mania and diabetic peripheral neuropathic pain. Additional preclinical and late-stage discovery stage programs are also underway, including targeting chronic pain and hearing disorders.

Webull offers Rapport Therapeutics Inc stock information, including NASDAQ: RAPP real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, RAPP stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading RAPP stock methods without spending real money on the virtual paper trading platform.